A randomized, double-blind, placebo controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active non-radiographic axial spondyloarthritis

Starting date
September 1, 2016
Duration (months)
60
Departments
Medicine
Managers or local contacts
Idolazzi Luca

Project participants

Luca Idolazzi
Temporary Assistant Professor
Research areas involved in the project
Rheumatology  (DM)
Rheumatology  (DNBM)

Activities

Research facilities